Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis-Reference-Cited by-同舟云学术

Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis

Published:2003-11 Issue:11 Volume:47 Page:3647-3650
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Dannaoui Eric¹,Meis Jacques F. G. M.²,Loebenberg David³,Verweij Paul E.¹

Affiliation:

1. Department of Medical Microbiology, University Medical Center, St. Radboud, 6500 HB Nijmegen

2. Department of Medical Microbiology, Canisius-Wilhelmina Hospital, 65000 GS Nijmegen, The Netherlands

3. Schering Plough Research Institute, Kenilworth, New Jersey 07033

Abstract

ABSTRACT Three isolates of zygomycetes were used to produce a disseminated infection in nonimmunocompromised mice. Against all zygomycete strains, amphotericin B significantly prolonged survival. Itraconazole was inactive against Rhizopus microsporus and Rhizopus oryzae but was partially active against Absidia corymbifera . Posaconazole had no beneficial effects against R. oryzae but showed partial activity against A. corymbifera . Posaconazole had a clear dose-response effect against R. microsporus .

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.47.11.3647-3650.2003

Reference28 articles.

1. In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida

2. Dannaoui, E., J. Meletiadis, J. W. Mouton, J. F. Meis, and P. E. Verweij. 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother.51:45-52.

3. Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis

4. In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens

5. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Computational Interaction Analyses of Some Vitamin D-Related Compounds with Sterol 14-Demethylase (CYP51) – Could It Be a Glimmer of Hope to Find New Anti-Mucormycotic Drugs Extracted from Plants-Derived Sterols?;Natural Product Communications;2024-01

2. Rhino-orbital-cerebral Mucormycosis and Aspergillosis Post-COVID-19: Contrariety in Terms of Prevalence Severity Management and Prognosis at a Tertiary Care Centre in Western Rajasthan;An International Journal of Otorhinolaryngology Clinics;2023-12-21

3. An extensive review on antifungal approaches in the treatment of mucormycosis;Journal of Biochemical and Molecular Toxicology;2023-06-22

4. Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents;European Journal of Medicinal Chemistry;2023-01

5. Mucormycosis;Diagnosis and Treatment of Fungal Infections;2023